Archives
How CSN2 Targeting Raises Rabbit Milk Yield
2026-11-17
A targeted endogenous milk-protein locus produced unusually high reporter concentrations in rabbit milk, but the result is best interpreted as a strong proof of concept rather than a universal production benchmark.
Why CSN2 Targeting Raised Rabbit Milk Output
2026-11-17
A 2025 study reported 15–20 g/L of a fluorescent recombinant protein in milk from two homozygous rabbits after targeted integration at the CSN2 locus. The result is a strong feasibility signal, but its comparison with conventional rabbit pharming remains indirect and does not yet establish performance across therapeutic proteins or production settings.
What High-Yield Rabbit Pharming Evidence Shows
2026-11-16
A targeted rabbit line produced a reported 15–20 g/L of tdTomato in milk from two homozygous females, substantially above the historical yields summarized in the study. The result supports the feasibility of coupling a milk-protein locus with targeted integration, but it is not yet a matched, generalizable comparison of therapeutic protein production.
Why mRNA-LNP Translation Depends on CMC
2026-11-16
A mechanistic editorial on how lipid chemistry, particle attributes, biological stability, and manufacturing comparability shape the translation of mRNA lipid nanoparticles.
How a CSN2 Knock-In Raised Rabbit Milk Output
2026-11-15
A 2025 study tested whether directing a reporter transgene to the endogenous CSN2 milk-protein locus could overcome the variable expression associated with conventional rabbit pharming. The resulting line produced 15–20 g/L tdTomato in milk from two homozygous females, an important proof of concept whose broader significance remains limited by the reporter-based design, small production cohort, and historical rather than side-by-side comparators.
When Context Changes What a Result Means
2026-11-14
A reported protein yield is not an isolated number. Its meaning depends on the biological model, genetic architecture, comparator, readout, and level of replication. The rabbit pharming study illustrates how a striking milk concentration can support a mechanistic proof of concept while remaining distinct from evidence of therapeutic-product performance.
HEPES and the Causal Limits of Rabbit Pharming
2026-11-13
A targeted CSN2 knock-in study reported unusually high tdTomato concentrations in rabbit milk, supporting a locus- and promoter-directed expression strategy. The result does not establish equivalent performance for therapeutic proteins or a causal role for HEPES, whose relevance belongs to pH-controlled measurement contexts.
What mRNA–LNP Comparisons Really Establish
2026-11-13
Published comparisons support lipid nanoparticles as the most clinically established non-viral delivery platform for mRNA, while also showing that delivery performance cannot be separated from tolerability, biodegradability, analytical control, and manufacturing comparability. The strongest conclusions concern mechanisms and translation constraints; direct quantitative evidence for universal superiority among carrier classes remains limited.
EX 527 and SIRT1 in Aging Bone: Reading the Evidence
2026-11-12
A literature-focused interpretation of how EX 527 (SEN0014196) functioned as a pharmacological SIRT1-inhibition comparator in an aging-bone study, linking SIRT1 activity with type H vessels, osteogenesis, β-catenin signaling, and reciprocal stromal–endothelial communication.
How LNP Chemistry Shapes mRNA Translation
2026-11-12
A mechanistic editorial on how lipid chemistry, nanoparticle attributes, physiological stability, and manufacturing controls shape the translation of mRNA delivery systems, with emphasis on what current review evidence establishes and where interpretation remains limited.
When Context Changes a Yield Result
2026-11-11
A reported 15–20 g/L milk concentration in a targeted rabbit line is best interpreted as a locus- and promoter-specific proof of concept, not a universal production benchmark. The meaning of the result changes with the reporter, genotype, comparator, measurement, and biological context.
Why CSN2 Targeting Raises Rabbit Pharming Yield
2026-11-11
A literature-focused analysis of how endogenous CSN2-locus targeting produced high tdTomato concentrations in rabbit milk, what the study demonstrates, and where its evidence remains limited.
How mRNA–LNP Quality Shapes Translation
2026-11-10
mRNA–lipid nanoparticles succeed when molecular design, particle attributes, physiological behavior, and manufacturing control remain causally aligned. The strongest evidence supports a systems-level interpretation: ionizable lipid chemistry can balance delivery and tolerability, but no single critical quality attribute independently predicts clinical performance.
What High-Yield Rabbit Pharming Evidence Shows
2026-11-10
A 2025 study reports that targeted placement of a reporter gene under the endogenous CSN2 regulatory context produced 15–20 g/L tdTomato in milk from two homozygous rabbits. The result supports a strong locus-and-promoter effect hypothesis, but it does not yet establish equivalent performance for therapeutic proteins, population-wide reproducibility, or manufacturing readiness.
HEPES and the Limits of Rabbit Pharming Evidence
2026-11-09
A targeted rabbit expression study reported unusually high milk concentrations of a fluorescent reporter, but its findings support a narrow promoter-and-locus proof of concept rather than evidence for HEPES, intracellular pH modulation, or therapeutic-protein production in general.